CCR2 and neoplasm: Although the Colon38 tumor model has a minimal regulatory T cell (Treg) component (Supplementary Figure S2), CCR2/CCR5 antagonism in tumors with abundant Tregs could offer additional benefits by targeting Tregs as well as IM post-RT and promote anti-tumor immunity by blocking two modes of immunosuppression.